A manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply obligations. Following allegations from its partners that the manufacturer was using the patent settlements to adversely affect competition, CRA’s analysis demonstrated that there was no anticompetitive effect and that the supply agreements enhanced efficiency and competition, particularly when considering the Drug Enforcement Agency’s quota system for active ingredient supply for Schedule II products.
What happens when AI sets wages
The authors fed 60,000 freelancer profiles into eight widely used LLMs, asking each model to recommend an hourly rate. From hourly wage setting to testing for...